Experimental studies have shown that TLR9 signaling influences miR-129-5p expression, with weak TLR9 agonists (e.g., BL-7040) modulating miR-129-5p levels to enhance cholinergic signaling and reduce inflammation in inflammatory diseases like IBD. The gene discussed is TLR9; the disease is inflammatory bowel disease.